Eleanor Leal
Nurse Practitioner · Bakersfield, CANPI 1174054076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 169 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 39 manufacturers, the largest accounting for just 11.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $1,738 and has fallen 53.2% since, to $814 in 2025. Among nurse practitioner clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 169 payments — averaging $39.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$767
- AstraZeneca$703
- Abbott$599
- Novartis$418
- Boehringer Ingelheim$312
- Cvrx, Inc.$259
- plus $4K from 33 others
What the payments were for
- Food & beverage$6,745100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 37 | $767 |
| AstraZeneca | 14 | $703 |
| Abbott | 18 | $599 |
| Novartis | 20 | $418 |
| Boehringer Ingelheim | 8 | $312 |
| Cvrx, Inc. | 2 | $259 |
| E.r. Squibb & Sons, L.L.C. | 3 | $259 |
| Teva Pharmaceuticals USA, Inc. | 2 | $249 |
| GSK | 2 | $249 |
| Regeneron Healthcare Solutions, Inc. | 2 | $240 |
| Inari Medical, Inc. | 2 | $223 |
| Heartflow, Inc. | 2 | $160 |
| Medtronic | 3 | $160 |
| ZOLL Respicardia, Inc. | 1 | $148 |
| Novo Nordisk | 4 | $133 |
| Neurocrine Biosciences, Inc. | 1 | $125 |
| Biohaven Pharmaceuticals, Inc. | 1 | $123 |
| Irhythm Technologies, Inc. | 5 | $123 |
| W. L. Gore & Associates, Inc. | 2 | $116 |
| AbbVie | 1 | $115 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 8 | $108 |
| Vapotherm Inc | 1 | $106 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $104 |
| Pfizer | 6 | $103 |
| Amgen | 4 | $99 |
| Aurinia Pharma U.S., Inc. | 1 | $99 |
| Lilly USA, LLC | 1 | $90 |
| Eisai Inc. | 1 | $80 |
| Silk Road Medical, Inc. | 1 | $80 |
| Scynexis, Inc. | 1 | $78 |
| Verrica Pharmaceuticals Inc. | 1 | $73 |
| Bayer | 4 | $69 |
| Boston Scientific | 2 | $39 |
| Scpharmaceuticals Inc. | 2 | $35 |
| Abiomed | 1 | $28 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Alnylam Pharmaceuticals Inc. | 1 | $20 |
| Daiichi Sankyo Inc. | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Barostim Neo System$259
- AUSTEDO$249
- DUPIXENT$240
- ANDEXXA$208
- FFRct$150
- remede System$148
- FLOWTRIEVER CATHETER, S$140
- CT THROMBECTOMY SYSTEM KIT$140
- TRELEGY ELLIPTA$125
- INGREZZA$125
- FARXIGA$125
- JARDIANCE$125
- BEXSERO$124
- NURTEC ODT$123
- Mavyret$115
- VAPOTHERM$106
- CAPLYTA$104
How this compares
$6,745 in reported general payments places this provider in the 95th percentile of 6,779 nurse practitioner providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 90 | $75,905 |
| FarxigaDapagliflozin Propanediol | 61 | $37,095 |
| EntrestoSacubitril/Valsartan | 29 | $25,069 |
| JardianceEmpagliflozin | 19 | $14,758 |
| XareltoRivaroxaban | 17 | $14,081 |
| Midodrine Hcl | 73 | $8,521 |
| Potassium Chloride | 34 | $3,389 |
| Atorvastatin Calcium | 250 | $1,594 |
| Rosuvastatin Calcium | 133 | $1,369 |
| Losartan Potassium | 188 | $1,289 |
| Nitroglycerin | 82 | $1,080 |
| Lisinopril | 158 | $962 |
| ClopidogrelClopidogrel Bisulfate | 113 | $956 |
| Isosorbide Dinitrate | 23 | $943 |
| Amlodipine Besylate | 231 | $880 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $103 | $75,90590 claims |
| AstraZenecaFarxiga | $703 | $37,09561 claims |
| NovartisEntresto | $418 | $25,06929 claims |
| Boehringer IngelheimJardiance | $312 | $14,75819 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,779 nurse practitioner providers in California.
Other nurse practitioner in Bakersfield
- Rhonda HewittStanford$917K
- Linda TrinhIrvine$884K
- Denise SinagaNorthridge$728K
- Debbie TaySanta Monica$642K
- Joe GorelickCampbell$638K
- Lynsey LakinArcadia$540K
- Kelly ChoiRancho Cucamonga$483K
- Hamta ZareStanford$428K
- Shawna ChrismanRoseville$425K
- Angelina CollinsSan Diego$356K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.